Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer
- 1 February 1989
- Vol. 63 (3) , 438-439
- https://doi.org/10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o
Abstract
High‐dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high‐dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.This publication has 3 references indexed in Scilit:
- High-Dose Megestrol AcetatePublished by American Medical Association (AMA) ,1987
- High-dose megestrol acetate. A possible treatment for cachexiaJAMA, 1987
- Megestrol acetateCancer Treatment Reviews, 1983